Ex Vivo-Generated Dendritic Cell-Based Vaccines in Melanoma: The Role of Nanoparticulate Delivery Systems

Purpose: Melanoma is a poorly immunogenic and highly aggressive skin cancer with limited long-term survival for advanced disease. Dendritic cell (DC)-based vaccines are promising immunotherapies, but their efficacy relies on critical factors including DC maturation state and efficient antigen delivery. Nanoparticulate delivery systems can enhance antigen delivery to ex vivo-generated DCs, mediate DC maturation (adjuvanticity), and promote cytoplasmic antigen presentation through MHC class I—potentially leading to potent antigen-specific immune responses. This review addresses the need to consolidate and evaluate the role of different nanoparticulate delivery systems in ex vivo-generated DC-based vaccines against melanoma. ---

Hypothesis: The review’s central thesis is: if nanoparticles (liposomes, polymeric nanoparticles, gold nanoparticles) are used as antigen delivery systems for ex vivo-generated DC-based vaccines in melanoma, then they can enhance antigen uptake, mediate DC maturation through intrinsic adjuvanticity, facilitate cross-presentation via MHC class I, and induce potent antigen-specific antitumor immune responses with prolonged survival. ---

Aims: - Summarize the role of different types of nanoparticulate antigen delivery systems used in ex vivo-generated DC-based vaccines against melanoma. - Describe their adjuvanticity in mediating DC maturation. - Explain cytoplasmic presentation of antigens to MHC class I molecules. - Present preclinical evidence of potent antigen-specific immune responses. - Discuss future perspectives, including combination with adjuvants or monoclonal antibodies. ---

Delivery system: Lipid-based systems: - Conventional liposomes (CLs): neutral phospholipid bilayers (phosphatidylcholine, cholesterol). - Fusogenic liposomes (FLs): CLs fused with UV-inactivated Sendai virus; enhance delivery and MHC class I presentation. - Cationic liposomes: DOTAP, DDA, DDAC; intrinsic adjuvanticity; DC maturation via CD80/CD86, IL-6, IL-12; Th1 polarization via P38 MAPK; CCL2 expression. - Mannosylated cationic liposomes: target C-type lectin receptors on DCs; enhanced uptake. - pH-sensitive liposomes: DOPE-based; transform from bilayer to hexagonal structure in acidic endosomes; promote MHC class I presentation. - Bubble liposomes (BLs): PEGylated liposomes filled with perfluoropropane gas; used with ultrasound for direct cytosolic antigen delivery. - Lipoplexes: DNA/RNA complexed with cationic lipids for DC transfection. Polymeric systems: - PLGA nanoparticles: FDA-approved, biodegradable, biocompatible; encapsulate antigens and adjuvants; sustained release; intrinsic adjuvanticity (CD40, CD80, CD86, MHC II upregulation). - Polyethyleneimine (PEI): cationic polymer; proton sponge effect; endosomal escape; used with chitosan. - Chitosan: natural linear polysaccharide; biodegradable, biocompatible; high amine density; adjuvanticity; low solubility at physiological pH limits application. - Chitosan-linked PEI (CP): combines advantages; high transfection efficiency, low cytotoxicity. Gold nanoparticles: - Gold glyconanoparticles (GNPs): 1–100 nm; carbohydrate surface for DC targeting; positive charge enhances uptake; adjuvanticity. - Mannose-mimicking shikimoyl ligand-conjugated AuNPs (AuNPs-SL): target DCs; deliver DNA vaccines. Payloads: Tumor cell lysates (TCLs), peptides (gp100, MART1, OVA, LLO91-99), proteins, DNA plasmids (pCMV-MART1, gp100), total RNA, mRNA. Targeting ligands: Mannose, shikimoyl, quinoyl, mannose-mimicking headgroups. ---

Approach: Narrative review of preclinical literature. No primary experimental groups. Model systems discussed include: - In vitro: DC2.4 mouse dendritic cell line, BMDCs, MoDCs, PBMCs. - In vivo: B16, B16F10, B16BL6, B16F1, B16-OVA murine melanoma models; metastatic and ectopic tumor models; prophylactic and therapeutic vaccination settings. - Disease context: Melanoma. - No clinical trials of nanoparticulate ex vivo DC-based vaccines in melanoma are reported; all studies are preclinical (murine). ---

Key methods: Techniques and endpoints highlighted across cited studies: - Flow cytometry for DC maturation markers (CD40, CD80, CD86, MHC I/II), transfection efficiency (GFP expression). - Confocal laser scanning microscopy (CLSM) for nuclear trafficking. - In vitro antigen presentation assays (IL-2 secretion by T cells). - In vivo tumor growth inhibition and survival analysis. - Metastasis quantification (lung metastasis frequency). - Cytokine production assays (IFN-γ, IL-12, TNF-α). - CTL response assays. - Uptake assays by DCs. ---

Key results: - Fusogenic liposomes (FLs): TCL/FLs-pulsed DCs significantly inhibited tumor growth until 17 days post-inoculation; superior to TCL/CLs-pulsed DCs. - Cationic liposomes (Srinivas et al.): Lipid 5 (shikimoyl headgroup) induced long-lasting immunity for 300 days post-tumor challenge in >80% of immunized mice with significant memory response (>6 months after second tumor challenge). - Cationic liposomes (Voshavar et al.): Lipid 5 protected 80% of ectopic and 75% of metastatic-challenged mice for 120 days and 150 days, respectively. - Bubble liposomes + ultrasound: Complete inhibition of tumor growth in 40% (2/5) of treated mice; fourfold decrease in B16/BL6 lung metastasis. - PLGA nanoparticles (Solbrig et al.): DCs loaded with PLGA co-encapsulated gp100, OVA, and B16 lysate provided greatest protection against future tumor growth; smallest tumor volume and longest tumor-free time. - Chitosan-linked PEI (Chen et al.): Higher transfection efficiency, lower cytotoxicity; 99.8% cell survival; slight tumor growth inhibition in B16BL6 model. - Gold glyconanoparticles (Calderon-Gonzalez et al.): DC-GNP-LLO91-99 diminished tumor size; 98% survival vs 85% for DC-LLO91-99. - AuNPs-SL (Meka et al.): Ten-fold higher transfection rate; prolonged survival until 200 days post-B16F10 challenge. ---

Interpretation: The authors conclude that nanoparticulate delivery systems—particularly cationic liposomes—are promising for ex vivo-generated DC-based vaccines against melanoma. These systems enhance antigen delivery, induce DC maturation, and mediate MHC class I presentation, leading to potent antigen-specific immune responses. Cationic liposomes were the most used approach due to their adjuvanticity, depot formation, and ease of manufacturing. The authors recommend further investigations to bring cationic liposome-incorporated DC-based immunotherapy into clinical trials for melanoma, and suggest combination with adjuvants, monoclonal antibodies, or targeted small molecules. ---

Limitations: - Preclinical only: All reviewed studies are in murine models; no clinical trials of nanoparticulate ex vivo DC-based vaccines in melanoma. - Time-consuming and expensive: Ex vivo generation of DC-based vaccines is labor-intensive and costly. - TME immunosuppression: Melanoma tumor microenvironment suppresses DC maturation and function, which ex vivo generation aims to overcome but adds complexity. - PLGA fabrication challenges: Use of organic solvents, high-speed mechanical agitation, or high temperature can cause protein degradation and destruction of antigen epitope recognition. - Chitosan limitations: Low solubility at physiological pH and low transfection efficiency. - PEI cytotoxicity: High-molecular-weight PEI has limited applicability due to cytotoxicity. - Cytokine storm risk: Antigen-specific immunotherapy, TLR agonists, and monoclonal antibody therapies may induce cytokine storm. - Lack of systematic comparison: No systematic comparative studies on critical factors (DC number, administration route, vaccination schedule) in melanoma. - As a review: Not a systematic review or meta-analysis; no primary data.